Pharma Aids Limited announcements
270 Dhaka Stock Exchange announcements for Pharma Aids Limited (PHARMAID) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (19).
- Trading of the shares of the company will resume on 10.12.2023.
Trading of the shares of the company will resume on 10.12.2023.
- Trading of the shares of the company will remain suspended on record date i.e., 07.12.2023.
Trading of the shares of the company will remain suspended on record date i.e., 07.12.2023.
- Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 05.12.2023 to 06.12.2023 and trading of the shares will remain suspended on record date i.e., 07.12.2023.
- The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the
The auditor of the company has given the \"Qualified Opinion\" paragraph in the Auditor\'s Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.dsebd.org/assets/pdf/Qualified\%20Opinion\%20of\%20Pharma\%20Aids\%20Limited\%20for\%20the\%20year\%20ended\%20on\%2030\%20June\%202023.pdf
- (Q1 Un-audited): EPS was Tk. 3.68 for July-September 2023 as against Tk. 1.99 for July-September 2022; NOCFPS was Tk. 3.
(Q1 Un-audited): EPS was Tk. 3.68 for July-September 2023 as against Tk. 1.99 for July-September 2022; NOCFPS was Tk. 3.29 for July-September 2023 as against Tk. 0.13 for July-September 2022. NAV per share was Tk. 94.95 as on September 30, 2023 and Tk. 91.28 as on June 30, 2023. (cont.)
- Q1 Financials
(Continuation news of PHARMAID): Reasons for significant deviation: EPS has increased compared to previous year due to increase in selling price of glass ampoules. NOCFPS has been increased compared to previous year due to decrease in tax payment and payment to suppliers. NAVPS has been increased due to overall increase in asset, mostly increase in Trade Receivables during the period. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- The Board of Directors has recommended 10\% cash dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Tim
The Board of Directors has recommended 10\% cash dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 11:30 AM, Venue: Digital Platform. Record date: 07.12.2023. The Company has reported EPS of Tk. (2.05), NAV per share of Tk. 91.28 and NOCFPS of Tk. 2.33 for the year ended June 30, 2023 as against Tk. 11.14, Tk. 98.83 and Tk. 10.85 respectively for the year ended June 30, 2022. The company has also informed that EPS & NPAT significantly decreased (cont.)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (08.11.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration
(Continuation news of PHARMAID): and became negative for following major reasons: reduction in sales due to hamper in production from frequent power cuts and gas supply shortage; radical increase in the cost of electricity, gas, and importing raw materials resulting from extreme increase in foreign exchange rate; payment of excessive advance tax in the form of TDS despite minimal profits; and most importantly, unchanged selling price of glass ampoules. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 07, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Board decision for toll manufacturing of glass ampoules
The company has informed that the Board of Directors of the Company has decided to come to an agreement with a private limited company for toll manufacturing of glass ampoules because the demand for glass ampoules is currently more than the company's production capacity. The toll manufacturing agreement shall be effective from October 1, 2023 for a trial period of 6 months till March 31, 2024, and may be revalidated subject to satisfactory outcome.
- (Q3 Un-audited): EPS was Tk. (1.21) for January-March 2023 as against Tk. 4.63 for January-March 2022; EPS was Tk. 0.05
(Q3 Un-audited): EPS was Tk. (1.21) for January-March 2023 as against Tk. 4.63 for January-March 2022; EPS was Tk. 0.05 for July 2022-March 2023 as against Tk. 15.31 for July 2021-March 2022. NOCFPS was Tk. 5.52 for July 2022-March 2023 as against Tk. 15.37 for July 2021-March 2022. NAV per share was Tk. 93.44 as on March 31, 2023 and Tk. 98.83 as on June 30, 2022. Reasons for deviation in EPS, NAVPS and NOCFPS: EPS has been decreased due to decrease of net sales, (cont.)
- Q3 Financials
(Continuation news of PHARMAID): increase of cost of raw materials, increase in gas consumption expense and unchanged selling price of glass ampoules. NAVPS has been decreased due to overall increase in liability, mostly for significant increase in short term loan (AIBL). NOCFPS has been decreased due to decrease in collection from sales and increase in payment to suppliers for import of glass tubes. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- (Q2 Un-audited): EPS was Tk. (0.76) for October-December 2022 as against Tk. 5.53 for October-December 2021; EPS was Tk.
(Q2 Un-audited): EPS was Tk. (0.76) for October-December 2022 as against Tk. 5.53 for October-December 2021; EPS was Tk. 1.23 for July-December 2022 as against Tk. 10.69 for July-December 2021. NOCFPS was Tk. 2.92 for July-December 2022 as against Tk. 14.56 for July-December 2021. NAV per share was Tk. 94.73 as on December 31, 2022 and Tk. 98.83 as on June 30, 2022. (cont.)
- Q2 Financials
(Continuation news of PHARMAID): Reasons for deviation in EPS and NOCFPS: EPS has been decreased due to decrease in net sales, increase in cost of goods sold, cost of raw materials, gas consumption, cost of fuel for production and increase in tax expense. NOCFPS has been decreased due to decrease in collection from sales, increase in payment to suppliers and increase in tax payment. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 21, 2023 at 11:30 AM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.